Article Text

Download PDFPDF

AB0408 Comparative effectiveness of abatacept versus tnfi in patients with rheumatoid arthritis who are ccp+ in the united states corrona registry
  1. L Harrold1,
  2. H Litman2,
  3. S Connolly3,
  4. E Alemao3,
  5. K Price3,
  6. S Kelly3,
  7. S Rebello2,
  8. W Hua2,
  9. J Kremer4
  1. 1University of Massachusetts, Worcester
  2. 2Corrona, LLC, Southborough
  3. 3Bristol-Myers Squibb, Princeton
  4. 4Albany Medical College and The Center for Rheumatology, Albany, United States


Background Anti-cyclic citrullinated peptide positivity (CCP+) is associated with a better response to abatacept (ABA) than anti-CCP negativity in patients (pts) with RA1,2; however, there are no head-to-head or comparative effectiveness research studies available evaluating responses to biologics in CCP+ pts in a real-world setting.

Objectives To compare the effectiveness of ABA vs a TNF inhibitor (TNFi) in pts with RA who are CCP+.

Methods We identified adult pts with RA from a large observational US cohort (1 Dec 2005–31 Aug 2016) who initiated ABA or a TNFi and who were CCP+ (≥20 U/mL) at or prior to initiation. Both groups had to have no prior exposure to other non-TNFi biologics or targeted synthetic DMARDs. TNFi initiators were excluded if they had prior use of ABA. Using propensity score matching (1:1) stratified by prior TNFi use (0, 1 and 2+), effectiveness at 6 months after initiation was evaluated. Mean change in CDAI over 6 months following initiation was the primary outcome, and secondary outcomes were: achievement of remission (CDAI ≤2.8), modified (m)ACR20, 50 and 70 responses and achievement of LDA/remission (CDAI ≤10) in those with moderate/high disease activity at initiation. A subset analysis was performed to consider separately pts who were biologic naïve and those who were biologic experienced at initiation.

Results The 330 pairs of propensity score-matched ABA and TNFi initiators had no substantial differences in baseline characteristics. Both treatment groups had similar mean change in CDAI at 6 months as well as achievement of LDA, remission and mACR20/50/70 responses (Table). Among the 97 matched biologic-naïve pairs, there was no significant difference in change in CDAI for ABA initiators vs TNFi initiators (p=0.19). However, in the 233 matched biologic-experienced pairs, those initiating ABA had a greater improvement in mean change in CDAI (p=0.033) and were more likely to achieve an mACR50 response (p=0.014).

Table 1

Conclusions Pts with RA who were CCP+ and received either ABA or TNFi had a substantial improvement in clinical disease activity. In the overall propensity score-matched sample, similar outcomes were observed for both treatment groups. However, analysis of the biologic-experienced cohort found that ABA initiators had a greater improvement in disease activity than TNFi initiators.


  1. Sokolove J, et al. Ann Rheum Dis 2016;75:709–14.

  2. Harrold LR, et al. Ann Rheum Dis 2016;75(Suppl 2):505–6.


Disclosure of Interest L. Harrold Shareholder of: Corrona, LLC, Grant/research support from: Pfizer, Consultant for: Roche, Employee of: Corrona, LLC, H. Litman Employee of: Corrona, LLC, S. Connolly Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, E. Alemao Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, K. Price Employee of: Bristol-Myers Squibb, S. Kelly Shareholder of: Bristol-Myers Squibb, Employee of: Bristol-Myers Squibb, S. Rebello Employee of: Corrona, LLC, W. Hua Employee of: Corrona, LLC, J. Kremer Shareholder of: Corrona, LLC, Grant/research support from: AbbVie, Genentech, Lilly, Novartis, Pfizer, Consultant for: AbbVie, Amgen, Bristol-Myers Squibb, Genentech, GSK, Lilly, MedImmune, Pfizer, Sanofi, Employee of: Corrona, LLC

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.